Company: VMCWF
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001641172-25-001827
Chunk: 13

Company: Valuence Merger Corp. I
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 13
---
., South Korea, Japan, Singapore, Indonesia, and Malaysia) and have begun to address
the challenges of an aging society through investments in research and development (“R&D”), especially around healthcare
and medicine. Moreover, we observed prior to our IPO that governments such as South Korea, Japan, and Singapore are driving growth and
accelerating R&D in technologies focused on pharmaceuticals, medical devices, and AI tools to support healthcare. Overall, we believe
these trends are driving the emergence of many attractive opportunities for investment in the space.

Within
biopharmaceuticals, the therapeutic areas of oncology, cardiology, infectious disease, immunology, and chronic disease such as obesity
and diabetes, continue to lead the market in terms of drug sales. We aim to examine these therapeutic areas as well as other areas of
high growth potential due to the significant aging population, especially in Alzheimer’s and other chronic diseases (e.g., fatty
liver disease, chronic kidney disease, idiopathic pulmonary fibrosis, etc.). In oncology, we believe that there are numerous attractive
opportunities around antibody drug conjugates, novel mechanisms and targets around protein degradation, and immunotherapies including
cancer vaccines, particularly with the success of mRNA vaccines for COVID-19 validating their potential for safety and efficacy. However,
we also believe that there are other potential attractive targets in oncology - one such example includes the growing areas of development
around fatty acid synthase (FASN) inhibitors and epigenetic regulators (e.g., PRMT5, METTL3, HDACs).

10

Precision
medicine is another area of continued growth with the advance of NGS testing, liquid biopsy, automation, and rapid testing as evidenced
during the COVID-19 pandemic. As “omics”-level research continues to advance, many attractive precision medicine companies
have emerged including those harnessing AI technology to better identify patients and predict outcomes across different indications,
such as cancer. Additionally, with the aging population, advancements in diagnostics (e.g., genetic screening) are providing actionable
genetic insights, enabling patients to identify potential disease risks and focus on preventative health treatments.

In
healthcare, the rapid uptake of digital and mobile health technology was catalyzed by the COVID-19 pandemic, and we believe the adoption
of these technologies will continue to grow. Furthermore, there is a greater need to closely monitor older patients through digital health
innovations to protect them from incidents and collect valuable health data that can be used